在线观看人与动牲交视频_夜夜高潮次次欢爽AV女_奇米在线视频观看_欧美精品七区_色悠久久综合网_少妇潮喷无码白浆水视频

德國Biontex 
德國Biontex是一家專門研制轉染試劑和技術的專業性企業,總部位于德國著名城市慕尼黑,其分支機構位于德國的商業中心法蘭克福;數年來他一如既往的為全球的科研用戶提供著世界一流的轉染試劑。METAFECTENE?,INSECTOGENE和DOTAP是其杰出的代表作;這三種轉染試劑分別用于哺乳動物細胞和昆蟲細胞的高效轉染。

The main entrance of the Innovations- und Gründerzentrum Biotechnologie (IZB) in Martinsried (www.izb-online.de), headquarters of Biontex Laboratories GmbH

Biontex Laboratories GmbH was launched in 1998 as a highly innovative biotech company in the field of genetic engineering. The company's operations focus on transfection, a field covering the introduction of genetic material (transfection) and proteins (proteofection) into eukaryotic cells. Biontex has the goal of continuously improving the success of this technology by advancing our synthetically produced carrier systems for nucleic acids and proteins and developing a variety of high-quality genetic engineering products. The current focus of our research is the development of all-new strategies to maximize the efficiency of transfection for any type of cells – in vivo or in vitro – by means of synthetic carrier components free from immunological effects.

Since healthy cells are essential for successful transfection, we supply both carrier reagents and products which enable mycoplasma-free cell culture. In addition, we produce derivatized agaroses for the purification of appropriately expressed proteins. Our range of products tailored to the requirements of microscopy make a significant contribution to this increasingly important visualization method.

In addition to simple operation, we focus on high efficiency combined with low toxicity and low immunological effects. For this reason, all our reagents are suitable for use as valuable aids in biological and pharmaceutical research. Biontex products have now been marketed globally for a decade and some have been licensed to globally operating partner companies with great success.

The core of our corporate philosophy is to provide our customers with the most efficient tools for successful transfection applications. To achieve this we also establish unbureaucratic partnerships with researchers seeking to test new applications using our products and thus providing validation.

By continuously improving our non-viral carrier systems, our ultimate aim is to help gene therapy to achieve a breakthrough – and this is our vision.